95.63+1.01 (+1.07%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 94.62 |
| Open | 95.61 |
| Bid | 94.61 x 800 |
| Ask | 96.49 x 800 |
| Day's Range | 95.42 - 96.54 |
| 52 Week Range | 69.18 - 99.84 |
| Volume | 2,400,039 |
| Avg. Volume | 1,906,369 |
| Market Cap | 218.399B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 30.98 |
| EPS (TTM) | 3.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.09 (3.23%) |
| Ex-Dividend Date | Mar 03, 2020 |
| 1y Target Est | 107.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-21% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Zacks
Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
- Zacks
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
- Investor's Business Daily
Beigene Stock Breaks Out To Record High On Cancer Drug OK In China
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.
© 2021 Verizon Media. All rights reserved.
